Evidence map›Paper›PMID 37975778›Full record

ArticleEuropean journal of neurology2024

Elevated serum neurofilament light chain protein in patients with essential tremor.

Sebastian Franthal, Michael Khalil, Daniela Kern, Lukas Gattermeyer, Arabella Buchmann, Petra Katschnig-Winter, Mariella Kögl, Rina Demjaha, Cansu Tafrali, Edith Hofer and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Sebastian FranthalDepartment of Neurology, Medical University of Graz, Graz, Austria.ORCID 0000-0001-7147-9037
Michael KhalilDepartment of Neurology, Medical University of Graz, Graz, Austria.
Daniela KernDepartment of Neurology, Medical University of Graz, Graz, Austria.
Lukas GattermeyerDepartment of Neurology, Medical University of Graz, Graz, Austria.
Arabella BuchmannDepartment of Neurology, Medical University of Graz, Graz, Austria.ORCID 0000-0002-7381-2427
Petra Katschnig-WinterDepartment of Neurology, Medical University of Graz, Graz, Austria.
Mariella KöglDepartment of Neurology, Medical University of Graz, Graz, Austria.
Rina DemjahaDepartment of Neurology, Medical University of Graz, Graz, Austria.
Cansu TafraliDepartment of Neurology, Medical University of Graz, Graz, Austria.
Edith HoferDepartment of Neurology, Medical University of Graz, Graz, Austria.
Reinhold SchmidtDepartment of Neurology, Medical University of Graz, Graz, Austria.
Petra SchwingenschuhDepartment of Neurology, Medical University of Graz, Graz, Austria.ORCID 0000-0002-3294-6824
Medical University of Graz · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeQuantification of neurofilament light chain protein in serum (sNfL) enables the neuro-axonal damage in peripheral blood to be reliably assessed and monitored. There is a long-standing debate whether essential tremor represents a 'benign' tremor syndrome or whether it is linked to neurodegeneration. This study aims to investigate sNfL concentrations in essential tremor compared to healthy controls (cross-sectionally and longitudinally) and to assess whether sNfL is associated with motor and nonmotor markers of disease progression.

methodsData of patients with essential tremor from our prospective registry on movement disorders (PROMOVE) were retrospectively analysed. Age-, sex- and body-mass-index-matched healthy controls were recruited from an ongoing community-dwelling aging cohort. sNfL was quantified by an ultra-sensitive single molecule array (Simoa). All participants underwent detailed clinical examination at baseline and after approximately 5 years of follow-up.

resultsThirty-seven patients with clinically diagnosed essential tremor were included and 37 controls. The essential tremor group showed significantly higher sNfL levels compared to healthy controls at baseline and follow-up. sNfL levels increased over time in both groups, and the slope of sNfL increase was similar in the essential tremor and healthy control groups. Comparing patients with a disease duration under 5 years to those with a longer disease duration, the former group had a significantly greater increase of sNfL over time, which strongly correlated to worsening of tremor and cognition.

conclusionOur findings indicate that neurodegeneration, possibly happening at an early disease stage, might play a role in the pathophysiology of essential tremor.

Indexed as

Essential TremorMultiple SclerosisBiomarkersHumansIntermediate FilamentsNeurofilament ProteinsRetrospective StudiesTremorBiomarkersNeurofilament Proteinsessential tremorneurodegenerationneurofilament light chain proteinpathophysiologysNfLtremor

Identifiers

PMID37975778
PMCPMC11235714
OpenAlexW4388783203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.